In the biotech and pharma industries, drug delivery is a crucial aspect of research and development. Finding new ways to deliver old drugs, ways to make a new drug more efficient or ways that make a...
The National Institutes of Health has persuaded 10 rival drugmakers to briefly set aside their competitive spirits and collaborate on drug discovery projects in four major diseases, pooling their data and expertise to kick-start early-stage efforts.
A few days ago, as Pfizer executives reviewed the pharma giant's numbers for 2013 and plans for 2014, analysts detected a growing willingness to see if they could hunt up an accelerated approval for palbociclib if the Phase II study for breast cancer rang up promising results.
Pfizer has spent the past few years trying to turn its sprawling, expensive R&D operation into an efficient, slimmed down drug development machine. The cost cutting side has gone well. Now it needs to show the R&D team can make money too by delivering a new wave of drugs and vaccines.
Pfizer made good last year on its promise to slash its R&D expenses to what it believes is a more sustainable figure, whacking about $800 million out of its research budget from the year before and settling into a sweet spot of $6.6 billion for 2013.
Pfizer is on a diet, and it shows. The company pumped up 2013 earnings despite a sizable slide in sales, thanks to layoffs and cost cuts, not to mention the successful spinoff of its animal health business, Zoetis. And it's looking for more of the same for 2014.
Pennsylvania's high court put drug design-defect claims on the menu for patients looking to sue for damages. In a closely watched case against Pfizer's Wyeth unit, the state Supreme Court reinstated claims that the company negligently designed and marketed a diet pill, Redux, that's now withdrawn from the market.
One of Pfizer's top cancer drug prospects in the late-stage pipeline failed the first two Phase III studies for non-small cell lung cancer, presenting the pharma giant with a key setback for its oncology group.
Pfizer posted some promising top-line results for a Phase III pain drug, an abuse-resistant formulation of oxycodone that sounds quite a bit like Remoxy, the long-delayed treatment codeveloped with Pain Therapeutics.
Pfizer celebrated three birthdays January 1. That's when it officially divided its business into three distinct units, each with its own management and financial reporting--and each with its own prospect of setting off on its own, at least eventually. Analysts are betting that one of those three businesses will be first to go: Already, potential buyers are buzzing.